Human serum albumin is the serum albumin found in human blood. It is the most abundant protein in human blood plasma; it constitutes about half of serum protein. It is produced in the liver. It is soluble and monomeric. Albumin transports hormones, fatty acids, and other compounds, buffers pH, and maintains oncotic pressure, among other functions. Albumin is synthesized in the liver as preproalbumin, which has an N-terminal peptide that is removed before the nascent protein is released from the rough endoplasmic reticulum. The product, proalbumin, is in turn cleaved in the Golgi vesicles to produce the secreted albumin. The reference range for albumin concentrations in serum is approximately 35 – 50 g/L (3.5 – 5.0 g/dL). It has a serum half-life of approximately 20 days. It has a molecular mass of 66.5 kDa. The gene for albumin is located on chromosome 4 and mutations in this gene can result in anomalous proteins. The human albumin gene is 16,961 nucleotides long from the putative ‘cap’ site to the first poly(A) addition site. It is split into 15 exons that are symmetrically placed within the 3 domains thought to have arisen by triplication of a single primordial domain.
Function • Maintains oncotic pressure • Transports thyroid hormones • Transports other hormones, in particular, ones that are fat-soluble • Transports fatty acids (“free” fatty acids) to the liver and to myocytes for utilization of energy • Transports unconjugated bilirubin • Transports many drugs; serum albumin levels can affect the half-life of drugs • Competitively binds calcium ions (Ca2+) • Serum albumin, as a negative acute-phase protein, is down-regulated in inflammatory states. As such, it is not a valid marker of nutritional status; rather, it is a marker of an inflammatory state • Prevents photodegradation of folic acid
Measurement Serum albumin is commonly measured by recording the change in absorbance upon binding to a dye such as bromocresol green or bromocresol purple.
Reference ranges Serum albumin concentration is typically 35 – 50 g/L (3.5 – 5.0 g/dL)
Pathology Hypoalbuminemia Hypoalbuminemia is a low blood albumin levels. This can be caused by: • Liver disease; cirrhosis of the liver is most common • Excess excretion by the kidneys (as in nephrotic syndrome) • Excess loss in bowel (protein-losing enteropathy, e.g., Ménétrier’s disease) • Burns (plasma loss in the absence of skin barrier) • Redistribution (hemodilution [as in pregnancy], increased vascular permeability or decreased lymphatic clearance) • Acute disease states (referred to as a negative acute-phase protein) • Malnutrition and wasting • Mutation causing analbuminemia (very rare) Hyperalbuminemia Hyperalbuminemia is an increased concentration of albumin in the blood. Typically, this condition is due to abrupt dehydration. Chronic dehydration needs to be treated with zinc as well as with water. Zinc reduces cell swelling caused by decreased intake of water (hypotonicity) and also increases retention of salt. In the dehydrated state, the body has too high an osmolarity and, it appears, discards zinc to prevent this. Zinc also regulates transport of the cellular osmolyte taurine, and albumin is known to increase cellular taurine absorption. Zinc has been shown to increase retinol (vitamin A) production from beta-carotene, and in lab experiments retinol reduced human albumin production. It is possible that a retinol (vitamin A) deficiency alone could cause albumin levels to become raised. Patients recovering from chronic dehydration may develop dry eyes as the body uses up its vitamin A store. Retinol causes cells to swell with water (this is most likely one reason that too much vitamin A is toxic). Hyperalbuminemia is also associated with high protein diets. Therapeutic uses Human albumin solution or HSA is available for medical use, usually at concentrations of 5-25%. Human albumin is often used to replace lost fluid and help restore blood volume in trauma, burns and surgery patients. A Cochrane systematic review] of 37 trials found no evidence that albumin, compared with cheaper alternatives such as saline, reduces the risk of dying. Human serum albumin has been used as a component of a frailty index. It has not been shown to give better results than other fluids when used simply to replace volume, but is frequently used in conditions where loss of albumin is a major problem, such as liver disease with ascites.
Glycation It has been known for a long time that human blood proteins like hemoglobin and serum albumin may undergo a slow non-enzymatic glycation, mainly by formation of a Schiff base between ε-amino groups of lysine (and sometimes arginine) residues and glucose molecules in blood (Maillard reaction). This reaction can be inhibited in the presence of antioxidant agents. Although this reaction may happen normally, elevated glycoalbumin is observed in diabetes mellitus. Glycation has the potential to alter the biological structure and function of the serum albumin protein. Moreover, the glycation can result in the formation of Advanced Glycation End-Products (AGE), which result in abnormal biological effects. Accumulation of AGEs leads to tissue damage via alteration of the structures and functions of tissue proteins, stimulation of cellular responses, through receptors specific for AGE-proteins, and generation of reactive oxygen intermediates. AGEs also react with DNA, thus causing mutations and DNA transposition. Thermal processing of proteins and carbohydrates brings major changes in allergenicity. AGEs are antigenic and represent many of the important neoantigens found in cooked or stored foods. They also interfere with the normal product of nitric oxide in cells. Although there are several lysine and arginine residues in the serum albumin structure, very few of them can take part in the glycation reaction. It is not clear exactly why only these residues are glycated in serum albumin, but it is suggested that non-covalent binding of glucose to serum albumin prior to the covalent bond formation might be the reason.
Loss via kidneys In the healthy kidney, albumin’s size and negative electric charge exclude it from excretion in the glomerulus. This is not always the case, as in some diseases including diabetic nephropathy, which can sometimes be a complication of uncontrolled or of longer term diabetes in which proteins can cross the glomerulus. The lost albumin can be detected by a simple urine test. Depending on the amount of albumin lost, a patient may have normal renal function, microalbuminuria, or albuminuria.
Interactions Human serum albumin has been shown to interact with FCGRT.
References
“Harmonisation of Reference Intervals” (PDF). pathologyharmony.co.uk. Pathology Harmony. Retrieved 23 June 2013.
Jump up^ “Albumin: analyte monograph” (PDF). Association for Clinical Biochemistry and Laboratory Medicine. Archived from the original (PDF) on 13 November 2012. Retrieved 23 June 2013.
Jump up^ Anderson, Douglas M. (2000). Dorland’s illustrated medical dictionary (29. ed.). Philadelphia [u.a.]: Saunders. p. 860. ISBN 0721682618.
^ Jump up to:a b Green P, Woglom AE, Genereux P, Daneault B, Paradis JM, Schnell S, Hawkey M, Maurer MS, Kirtane AJ, Kodali S, Moses JW, Leon MB, Smith CR, Williams M (2012). “The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience”. JACC Cardiovascular Interventions. 5 (9): 974–981. doi:10.1016/j.jcin.2012.06.011. PMC 3717525. PMID 22995885.
^ Jump up to:a b Walker, edited by H. Kenneth; Hall, W. Dallas; Schlossberg, J. Willis Hurst ; illustrations by Leon; Boyter, Charles H. (1990). Clinical methods : the history, physical, and laboratory examinations (3rd ed.). Boston: Butterworths. p. Chapter 101. ISBN 040990077X.
Jump up^ Masaki T, Matsuura T, Ohkawa K, Miyamura T, Okazaki I, Watanabe T, Suzuki T (July 2006). “All-trans retinoic acid down-regulates human albumin gene expression through the induction of C/EBPβ-LIP”. Biochem. J. 397 (2): 345–53. doi:10.1042/BJ20051863. PMC 1513275. PMID 16608438.
Jump up^ Pasantes-Morales H, Wright CE, Gaull GE (December 1984). “Protective effect of taurine, zinc and tocopherol on retinol-induced damage in human lymphoblastoid cells”. J. Nutr. 114 (12): 2256–61. PMID 6502269.
Jump up^ Mutlu EA, Keshavarzian A, Mutlu GM (June 2006). “Hyperalbuminemia and elevated transaminases associated with high-protein diet”. Scand. J. Gastroenterol. 41 (6): 759–60. doi:10.1080/00365520500442625. PMID 16716979.
Jump up^ The Albumin Reviewers (Alderson P, Bunn F, Li Wan Po A, Li L, Pearson M, Roberts I, Schierhout G). Human albumin solution for resuscitation and volume expansion in critically ill patients” Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001208. doi:10.1002/14651858.CD001208.pub2.
Jump up^ Rahbar S (October 1968). “An abnormal hemoglobin in red cells of diabetics”. Clin. Chim. Acta. 22 (2): 296–8. doi:10.1016/0009-8981(68)90372-0. PMID 5687098.
^ Jump up to:a b Day JF, Thorpe SR, Baynes JW (February 1979). “Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum”. J. Biol. Chem. 254 (3): 595–7. PMID 762083.
^ Jump up to:a b c Iberg N, Flückiger R (October 1986). “Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites”. J. Biol. Chem. 261 (29): 13542–5. PMID 3759977.
Jump up^ Jakus V, Hrnciarová M, Cársky J, Krahulec B, Rietbrock N (1999). “Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity”. Life Sci. 65 (18–19): 1991–3. doi:10.1016/S0024-3205(99)00462-2. PMID 10576452.
Jump up^ Mohamadi-Nejad A, Moosavi-Movahedi AA, Hakimelahi GH, Sheibani N (September 2002). “Thermodynamic analysis of human serum albumin interactions with glucose: insights into the diabetic range of glucose concentration”. Int. J. Biochem. Cell Biol. 34 (9): 1115–24. doi:10.1016/S1357-2725(02)00031-6. PMID 12009306.
Jump up^ Shaklai N, Garlick RL, Bunn HF (March 1984). “Nonenzymatic glycosylation of human serum albumin alters its conformation and function”. J. Biol. Chem. 259 (6): 3812–7. PMID 6706980.
Jump up^ Mendez DL, Jensen RA, McElroy LA, Pena JM, Esquerra RM (December 2005). “The effect of non-enzymatic glycation on the unfolding of human serum albumin”. Arch. Biochem. Biophys. 444 (2): 92–9. doi:10.1016/j.abb.2005.10.019. PMID 16309624.
Jump up^ Mohamadi-Nejada A, Moosavi-Movahedi AA,Safariana S, Naderi-Maneshc MH, Ranjbarc B, Farzamid B, Mostafavie H, Larijanif MB, Hakimelahi GH, A (July 2002). “The thermal analysis of nonezymatic glycosylation of human serum albumin: differential scanning calorimetry and circular dichroism studies”. Thermochimica Acta. 389 (1–2): 141–151. doi:10.1016/S0040-6031(02)00006-0.
Jump up^ Kańska U, Boratyński J (2002). “Thermal glycation of proteins by D-glucose and D-fructose”. Arch. Immunol. Ther. Exp. (Warsz.). 50 (1): 61–6. PMID 11916310.
Jump up^ Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K (February 2000). “Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products”. Circ. Res. 86 (3): E50–4. doi:10.1161/01.RES.86.3.e50. PMID 10679490.
Jump up^ Garlick RL, Mazer JS (May 1983). “The principal site of nonenzymatic glycosylation of human serum albumin in vivo”. J. Biol. Chem. 258 (10): 6142–6. PMID 6853480.
Jump up^ Marashi SA, Safarian S, Moosavi-Movahedi AA (2005). “Why major nonenzymatic glycation sites of human serum albumin are preferred to other residues?”. Med. Hypotheses. 64 (4): 881. doi:10.1016/j.mehy.2004.11.007. PMID 15694713.
Jump up^ Microalbumin Urine Test
Jump up^ Universal protein resource accession number P02768 for “Serum albumin” at UniProt.
Jump up^ Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL (February 2003). “The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan”. J. Exp. Med. 197 (3): 315–22. doi:10.1084/jem.20021829. PMC 2193842. PMID 12566415.